Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction between vigabatrin and phenytoin.

E M Rimmer1, A Richens

  • 1Department of Pharmacology and Therapeutics, University of Wales College of Medicine, Heath Park, Cardiff.

British Journal of Clinical Pharmacology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of generic substitution of anticonvulsants on the treatment of epilepsy.

CNS drugs·2013
Same author

Inhibition of phenytoin metabolism by sulthiame in epileptic patients.

British journal of clinical pharmacology·2012
Same author

Effect of diazepam on oculomotor balance.

British journal of clinical pharmacology·2012
Same author

Rate of elimination of tracer doses of phenytoin at different steady-state serum phenytoin concentrations in epileptic patients.

British journal of clinical pharmacology·2012
Same author

The influence of elevated plasma hydrocortisone concentrations on antipyrine metabolism in man.

British journal of clinical pharmacology·2012
Same author

α-adrenoceptor blocking drugs, pressor responses to noradrenaline, and the ankle jerk in man.

British journal of clinical pharmacology·2012
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
Same journal

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
See all related articles

Vigabatrin significantly reduces plasma phenytoin concentrations in epileptic patients by 23%. The exact mechanism behind this drug interaction remains unclear despite investigations into metabolic and protein binding pathways.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Neuroscience

Background:

  • Phenytoin is a widely used antiepileptic drug.
  • Vigabatrin is another antiepileptic medication.
  • A potential drug interaction between vigabatrin and phenytoin has been suggested.

Purpose of the Study:

  • To investigate the mechanism of vigabatrin-induced reduction in plasma phenytoin concentrations.
  • To assess changes in phenytoin pharmacokinetics during co-administration with vigabatrin.

Main Methods:

  • Eight epileptic patients receiving phenytoin therapy were treated with vigabatrin for 5 weeks.
  • Plasma phenytoin concentrations were monitored throughout the treatment period.
  • Plasma protein binding of phenytoin, urinary metabolite ratios, and antipyrine clearance were measured.

Related Experiment Videos

Main Results:

  • A significant mean reduction of 23% in total plasma phenytoin concentration was observed by the fifth week of vigabatrin treatment.
  • No significant changes were detected in plasma protein binding of phenytoin, the ratio of phenytoin to its major metabolite in urine, or antipyrine clearance.

Conclusions:

  • A drug interaction between vigabatrin and phenytoin, leading to decreased plasma phenytoin levels, is confirmed.
  • The mechanism underlying this interaction was not elucidated by the measured pharmacokinetic parameters.